Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
GHRP-6 vs Hexarelin
An educational, source-based comparison of GHRP-6 and Hexarelin — how each peptide works, what it's researched for, and what to know before going deeper.
A hexapeptide ghrelin receptor (GHS-R1a) agonist that stimulates pituitary GH release and increases appetite via central ghrelin pathways. One of the earliest GH-releasing peptides studied.
- Endogenous GH pulse stimulation
- Appetite stimulation in cachexia models
- Cardioprotective signaling (preclinical)
- • Increases appetite and may elevate cortisol/prolactin more than newer secretagogues.
- • Not FDA-approved; banned by WADA.
A synthetic hexapeptide and potent GHS-R agonist. Stimulates GH release more strongly than GHRP-6 and shows cardioprotective signaling in preclinical ischemia-reperfusion models, partly independent of GH.
- GH release
- Cardiac ischemia-reperfusion (preclinical)
- Left ventricular function in animal models
- • Not FDA-approved.
- • Tachyphylaxis with prolonged use.
- • Prohibited by WADA.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| GHRP-6 | GHRP-6 and the ghrelin receptor: cardiometabolic effects | Cardiovascular Research | 2010 | Review of GH-independent cardioprotective signaling observed in animal models. |
| Hexarelin | Hexarelin and the cardiovascular system | Cardiovascular Research | 2006 | Reviewed direct cardioprotective effects of hexarelin in animal models. |
Side-effect & safety grid
- Increases appetite and may elevate cortisol/prolactin more than newer secretagogues.
- Not FDA-approved; banned by WADA.
- Not FDA-approved.
- Tachyphylaxis with prolonged use.
- Prohibited by WADA.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
GHRP-6 vs Hexarelin — Key differences
- Class: GHRP-6 is classified as Growth Hormone Axis, while Hexarelin is Growth Hormone Axis · Cardiac.
- Primary research focus: GHRP-6 — endogenous gh pulse stimulation; Hexarelin — gh release.
- Tag: Growth hormone · Appetite vs Growth hormone.